Communication between health-care professionals and individuals with cancer regarding the effects of treatment on sexual ...

REDWOOD CITY, CA, USA I March 31, 2025 I Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development ...

Here are some stocks on the move for Monday, March 31. Yum Brands (YUM) is searching for a new CEO as current head David ...

Ovarian cancer is the fifth leading cause of cancer-related deaths among women in the U.S. However, the racial bias makes it ...

A woman's story of literal strength shows how ovarian cancer can be missed—and the lighthearted recovery milestone every care ...

Evaluation of nemvaleukin for platinum-resistant ovarian cancer will be terminated based on OS data from an interim analysis ...

A common blood test for ovarian cancer is more likely to fall short for Black and Native American women, according to a new ...

A common blood test may miss ovarian cancer in some Black and Native American patients, delaying their treatment, a new study ...

The trial is designed to address a broad and underserved pool of ovarian cancer patients with no approved standard of care therapies. The inclusion criteria allows patients to enroll regardless of (i) ...

Mural Oncology said that it won't continue developing its ovarian cancer drug candidate Nemvaleukin to be used in conjunction with Merck's Keytruda after results showed no statistical improvement in ...

Black and American Indian patients are less likely to have elevated cancer antigen (CA)-125 levels at ovarian cancer ...